INTRODUCTION {#sec1}
============

rostate cancer is the second most common cancer diagnosed in men worldwide \[[@cit0001]\]. A growing awareness of prostate cancer stimulated development of different treatment modalities, resulting in an increasing overall survival \[[@cit0001], [@cit0002]\]. Despite a good overall survival, patients with prostate cancer often have a high rate of morbidity \[[@cit0003]\]. Particularly androgen deprivation therapy has been shown to cause significant side effects including unfavorable changes in body composition (decreased muscle and bone mass, increased body fat), fatigue, sexual dysfunction and a reduced health-related quality of life \[[@cit0004]\]. Several studies suggest that early initiated physical training is beneficial in preventing androgen deprivation therapy-related side effects \[[@cit0005], [@cit0006], [@cit0007]\]. Furthermore, different authors have demonstrated significant gains in fitness and quality of life as a result of physical exercise in this population \[[@cit0003], [@cit0008]\].

The primary aim of this pilot study is to describe the influence of a six-month supervised physical exercise program on the physical and cardio-metabolic profile in patients with prostate cancer on androgen deprivation therapy. Furthermore, we wanted to evaluate if the expected effect persists three months after training cessation. The secondary goal was to determine the effect of the supervised physical exercise program on quality of life.

MATERIAL AND METHODS {#sec2}
====================

With this pilot study, we want to present the data from a six-month supervised physical exercise program at the Antwerp University Hospital, which combined a range of aerobic and resistance exercises and evaluated the benefit of physical exercise regarding the general health status, physical function and quality of life in men with prostate cancer undergoing androgen deprivation therapy.

After approval by the Ethics Committee (n° 13/40/384), a total of 70 patients were invited to participate in our pilot study between October 2014 and March 2016. The physical exercise program was established in cooperation with the Multidisciplinary Oncological Center of Antwerp, the department of Urology and the department of Physical Medicine and Rehabilitation (Antwerp University Hospital, Edegem, Belgium).

Inclusion criteria was age ≥50 years, histological diagnosis of prostate cancer with or without metastasis and an androgen deprivation therapy-exposure of ≥six months. Exclusion criteria were previous diagnosis of any cancer other than prostate cancer and pre-existing cardiovascular or metabolic disease. Our final study-population consisted of 27 patients. The main reasons for declining the invitation was lack of interest or inability to reach the hospital on a regular basis due to transportation problems and fear of injuries. All included patients provided a written informed consent.

Pre-training assessment included an anthropometrical assessment (body mass index, abdominal circumference and blood pressure), physical fitness and a fasting blood sample containing a lipid profile (total cholesterol, triglycerides, low-density lipoproteins and high-density lipoproteins) and a glucose profile (HbA1c and glycaemia). An EORTC-C30 (European Organization for Research and Treatment of Cancer) questionnaire V.3 was used to assess the baseline quality of life in all patients. This questionnaire incorporates 15 multi-item scales: Global health status / quality of life scale, five functional scales (Physical, Role, Emotional, Cognitive and Social) and nine symptom scales (Fatigue, Nausea or Vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Constipation, Diarrhea and Financial difficulties) \[[@cit0009]\]. Physical fitness was assessed by isometric muscle strength measurements (joint angle of 90° for knee and elbow flexion, and 45° for knee extension) using a Primus RS dynamometer (BTE Technologies Inc., Hanover, MD, USA).

A 30-seconds single leg balance test was carried out, i.e. the number of attempts needed to accumulate a total stable balance time of 30 seconds while standing on one foot with closed eyes. Blood analysis was repeated at three-month follow-up. Anthropometrical parameters, physical fitness and quality of life were recorded at the three-month, six-month and nine-month follow-up ([Table 1](#t0001){ref-type="table"}).

###### 

Summary of the measurements and time points

  -------------------------------------------------------------------------------------------------------------
  Measure/Domain                                                                            T0   T3   T6   T9
  ----------------------------------------------------------------------------------------- ---- ---- ---- ----
  General information\                                                                      \              
  Date of birth\                                                                            X\             
  Tumor-stage\                                                                              X\             
  Gleason score\                                                                            X\             
  Androgen deprivation therapy\                                                             X\             
  duration (months)\                                                                        \              
  Previous prostate cancer treatment                                                        X              

  Anthropometricals\                                                                        \    \    \    \
  Weight (kg)\                                                                              \    \    \    \
  Length (m)\                                                                               X\   X\   X\   X\
  Body mass index (kg/m²)\                                                                  X\   X\   X\   X\
  Abdominal circumference (cm)\                                                             X\   X\   X\   X\
  Blood pressure :\                                                                         X\   X\   X\   X\
  Systolic (mmHg)\                                                                          X\   X\   X\   X\
  Diastolic (mmHg)\                                                                         \    \    \    \
  Resting heart rate (bps)                                                                  X    X    X    X

  Biologicals\                                                                              \    \         
  Glucose (mg/dl)\                                                                          X\   X\        
  HbA1c (mg/dl)\                                                                            X\   X\        
  Cholesterol (mg/dl)\                                                                      X    X         
  (total cholesterol, high-density lipoproteins, low-density lipoproteins, triglycerides)                  

  Physical Fitness\                                                                         \    \    \    \
  Balance 30sec\                                                                            X\   X\   X\   X\
  Power (Nm)\                                                                               X\   X\   X\   X\
  Flexion knee (right/left)\                                                                X\   X\   X\   X\
  Extension knee (right/left)\                                                              X\   X\   X\   X\
  Flexion elbow (right/left)                                                                X    X    X    X

  EORTC-C30 score\                                                                          \    \    \    \
  Functional scale (%)\                                                                     X\   X\   X\   X\
  Symptom scale (%)\                                                                        X\   X\   X\   X\
  Quality of Life scale (%)                                                                 X    X    X    X
  -------------------------------------------------------------------------------------------------------------

The 27 patients were divided into four groups of six to eight patients. Prior to the physical exercise program, a Conconi test (relationship between running speed and individual heart rate) was performed to identify the individual aerobic threshold. The exercises were adjusted to this heart rate, targeting the best training outcome.

The patients had supervised training sessions of two hours for a six-month period (twice weekly for three months, followed by once weekly for another three months). The training sessions were conducted at the department of Physical Medicine and Rehabilitation of the Antwerp University Hospital, according to the "General Sports Medicine Guidelines for Cancer Survivors" \[[@cit0010]\]. Each training session included moderate to high intensity aerobic and resistance exercises. The 45-minute aerobic section of the program was modified for each patient according to their individual interest or capacity, varying between intervals of cycling, walking or jogging at ±80% of their maximum heart rate. The resistance exercises consisted of leg extensions, leg presses, leg curls, chest presses, seated presses, triceps flexes and triceps extensions.

SPSS V.21 (IBM Corp, Armonk, NY, USA) was used to perform statistical analysis. A p-value ≤0.05 was considered statistically significant. A Shapiro-Wilk test (p \>0.05) and a visual inspection of their histograms, normal Q-Q plots showed that our variables were approximately normally distributed for different time measurements (T0 -- T3 -- T6 -- T9). A one-way repeated measures ANOVA was used to compare means. Post-hoc analyses were used in case of significant differences in measurements, with a significance level of 0.05 and a confidence interval of 95%. We represent the p-value of adjusted group difference in mean change over several months (Bonferroni test).

RESULTS {#sec3}
=======

Baseline ([Table 2](#t0002){ref-type="table"}) {#sec3.1}
----------------------------------------------

Twenty-seven patients were included in this pilot study. Mean age was 71.4 ±6.2 years. The largest part of the group consisted of patients with localized prostate cancer (80%) and radiation was the major treatment prior to androgen deprivation therapy (88%). The mean duration of androgen deprivation therapy before entering the study was 30.96 months. Around 62.5% of the study-population used goserelin acetate long-acting implants in monotherapy, where 33.3% used goserelin acetate long-acting implants in combination with either bicalutamide 50 mg (16%), abiraterone acetate 1000 mg and prednisolone 10 mg (8.7%) or cyproterone acetate 50 mg (8.6%). Finally, 4.2% of our study-population used degarelix 80 mg once monthly.

###### 

Baseline characteristics

  ---------------------------------------------------------
                                            N = 27   
  ----------------------------------------- -------- ------
  Age (y)                                   71.4     6.2

  Cancer stage\                             80%\     
  Recurrent localized (%)\                  8%\      
  Nodal metastases (%)\                     12%      
  Bone metastases (%)\                               
  Gleason score                                      

  7                                         1.2      

  Previous radiation (%)                    88%\     
                                            28%      

  Previous prostatectomy(%)                          

  Height (cm)                               173      5

  Weight (kg)                               86.2     9.3

  Body mass index (kg/m²)\                  29       3
  Underweight (\<18.5)\                              
  Normal weight (18.5--24.9)\                        
  Overweight (25--29.9)\                             
  Obese (≥30)                                        

  0%\                                                
  4%\                                                
  64%\                                               
  32%                                                

  Abdominal circumference (cm)\             106.7    8.9
  ≥102 cm                                            

  68%                                                

  Known diabetes\                           \        
  yes\                                      19%\     
  no                                        81%      

  Systolic blood pressure (mmHg)\           144      20
  Normal blood pressure (\<120 mmHg)\                
  Pre-hypertension (120--139 mmHg)\                  
  Stage 1 hypertension (140--159mmHg)\               
  Stage 2 hypertension (≥60 mmHg)                    

  8%\                                                
  28.\                                               
  48%\                                               
  16%                                                

  Diastolic blood pressure (mmHg)\          76       9
  Normal blood pressure (\<80 mmHg)\                 
  Pre-hypertension (80--89 mmHg)\                    
  Stage 1 hypertension (90--99 mmHg)\                
  Stage 2 hypertension (≥100 mmHg)                   

  64%\                                               
  16%\                                               
  8%\                                                
  0%                                                 

  Blood sample\                             \        
  Fasting glucose\                          \        
  Normal (70 to 100 mg/dl)\                 56%\     
  Pre-diabetes (101 to 126 mg/dl)\          16%\     
  Diabetes (\>126 mg/dl)\                   28%\     
  HbA1c\                                    \        
  Increased risk of diabetes (5.7--6.4%)\   56%\     
  Diabetes (\>6.5%)\                        28%\     
  Cholesterol\                              \        
  Total cholesterol ≥200 mg/dl\             36%\     
  Low-density lipoproteins ≥130 mg/dl\      36%\     
  High-density lipoproteins ≤40 mg/dl\      40%\     
  Triglycerides ≥200 mg/dl                  32%      

  EORTC-C30\                                \        \
  Functional scale (%)\                     79%\     13%\
  Symptom scale (%)\                        17%\     10%\
  Quality of life scale (%)                 66%      15%
  ---------------------------------------------------------

We noticed a mean body mass index of 29 ±3 kg/m^2^, which indicates that the majority of our study-population was overweight (64%) or obese (32%). As a consequence, 68% of the study-population had an abdominal circumference ≥102 cm, indicating a higher risk for cardiovascular diseases and type two diabetes mellitus. Prior to inclusion, only five patients (18.5%) were known to have diabetes. However, based on our blood sample values (HbA1c), 28% were categorized in the diabetes group, while 56% were at increased risk to develop diabetes. 36% of our study-population had a total cholesterol ≥200 mg/dl, low-density lipoproteins ≥130 mg/dl, high-density lipoproteins ≤40 mg/dl and triglycerides ≥200 mg/dl. The mean systolic blood pressure was 144 ±20 mmHg and the mean diastolic blood pressure was 76 ±9 mmHg. Concerning the systolic blood pressure, 64% of the patients had hypertension (48% had stage 1 hypertension and 16% had stage 2 hypertension). The average self-reported quality of life was 66%. The average scores for the functional scale and symptom scale were 79% and 17%, respectively.

Drop-out rate {#sec3.2}
-------------

Seven patients left the training program after six months because of different factors and did not return for the nine-month follow-up assessment. The major reasons for leaving the study-protocol were a lack of interest and disease progression. We emphasize that only two third of the patients (18/27) returned for the nine-month follow-up assessment. No adverse events occurred during the training program.

Evolution in metabolic profile ([Table 3](#t0003){ref-type="table"}) {#sec3.3}
--------------------------------------------------------------------

The baseline mean body mass index and mean abdominal circumference were 29.1 kg/m^2^ (range 22.4--35.2) and 106.7 cm (range 93.0--125.0), respectively. We notice a statistically significant decrease in mean body mass index (28.7 kg/m^2^ (range 21.9--35.4); p \<0.001) and mean abdominal circumference (104.3 cm (range 91.0--123.0); p \<0.001) at the three-month follow-up. Based on these results, it seems that further training continues to improve those parameters. However, because of a high nine-month follow-up dropout rate, these findings could not be supported on a statistic level.

###### 

Evolution in metabolic profile after 6 month of exercise training

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 T0 Mean \[min--max\]   T3 Mean \[min--max\]   T6 Mean \[min--max\]   T9 Mean \[min--max\]   Group difference in mean change T0 ≥ T3 (p value)   Group difference in mean change T3 ≥ T6 (p value)   Group difference in mean change T6 ≥ T9 (p value)
  ------------------------------ ---------------------- ---------------------- ---------------------- ---------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Body mass index (kg/m²)        29.1\                  28.7\                  27.9\                  27.9\                  \<0.001                                             1.00                                                1.00
                                 \[22.4--35.2\]         \[21.9--35.4\]         \[21.8--34.4\]         \[22.1--33.7\]                                                                                                                 

  Abdominal circumference (cm)   106.7\                 104.3\                 101.5\                 102.1\                 \<0.001                                             0.78                                                1.00
                                 \[93.0--125.0\]        \[91.0--123.0\]        \[91.0--114.0\]        \[90.0--116.0\]                                                                                                                

  Lipid profile (mg/dl)                                                                                                                                                                                                              

  Total cholesterol              189.7\                 193.4\                                                               0.55                                                                                                    
                                 \[121.0 --293.0\]      \[105.0--313.0\]                                                                                                                                                             

  Low-density lipoproteins       116.9\                 121.0\                                                               0.54                                                                                                    
                                 \[50.0--250.0\]        \[17.0--226.0\]                                                                                                                                                              

  High-density lipoproteins      49.9\                  51.5\                                                                0.36                                                                                                    
                                 \[27.0--79.0\]         \[27.0--95.0\]                                                                                                                                                               

  Triglycerides                  178.2\                 129.7\                                                               0.19                                                                                                    
                                 \[46.0--428.0\]        \[58.0--322.0\]                                                                                                                                                              

  Fasting glucose (mg/dl)        116.6\                 115.8\                                                               0.91                                                                                                    
                                 \[80.0--255.0\]        \[83.0--224.0\]                                                                                                                                                              

  HbA1c (mg/dl)                  6.3\                   6.1\                                                                 0.07                                                                                                    
                                 \[5.5--10.0\]          \[4.6--8.3\]                                                                                                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Blood samples at the three-month follow-up showed no statistically significant changes. Baseline mean total cholesterol, mean low-density lipoproteins, mean high-density lipoproteins and mean triglycerides were 189.7 mg/dl (range 121.0--293.0), 116.9 mg/dl (range 50.0--250.0), 49.9 mg/dl (range 27.0--79.0) and 178.2 mg/dl (range 46.0--428.0), respectively. Whereas at the three-month follow-up we found a mean total cholesterol of 193.4 mg/dl (range 105.0--313.0; p = 0.55), mean low-density lipoproteins of 121.0 mg/dl (range 17.0--226.0; p = 054), mean high-density lipoproteins of 49.9 mg/dl (range 27.0--95.0; p = 0.36) and mean triglycerides of 129.7 mg/dl (range 58.0--322.0; p = 0.19). Similar results were found for the glucose profile. Fasting glucose (p = 0.91) was 116.6 (range 80.0--255.0) and 115.8 (range 83.0--224.0) and HbA1c (p = 0.07) was 6.3 mg/dl (range 5.5--10.0) and 6.1 mg/dl (range 4.6--8.3) at baseline and three-month follow-up, respectively. Yet some remarkably high values were observed (fasting glucose of 224 mg/dl, total cholesterol of 313 mg/dl and triglycerides of 428 mg/dl), indicating a poorly controlled metabolic profile in some individuals.

Evolution in physical performance and fitness ([Table 4](#t0004){ref-type="table"}) {#sec3.4}
-----------------------------------------------------------------------------------

Resting heart rate (baseline: 76 bps; range 50--112), muscle strength (baseline 103 Nm; range 60--150) and 30-second balance test (baseline 11; range 1--16) improved significantly at the three-month follow-up (75 bps (range 58--102); p = 0.03, 120 (range 80--160); p = 0.01 and 6 (0--13); p = 0.04, respectively). No significant difference was found at six-month follow-up or nine-month follow-up. Furthermore, no statistical significant differences were found for flexion and extension test results at three, six or nine-month follow-up, nor any significant differences in left versus right performance.

###### 

Evolution of physical performance and fitness after 6 month of exercise training

                             T0 Mean \[min--max\]   T3 Mean \[min--max\]   T6 Mean \[min--max\]   T9 Mean \[min--max\]   Group difference in mean change T0 ≥ T3 (p value)   Group difference in mean change T3 ≥ T6 (p value)   Group difference in mean change T6 ≥ T9 (p value)
  -------------------------- ---------------------- ---------------------- ---------------------- ---------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Resting heart rate (bpm)   76 \[50--112\]         75 \[58--102\]         73 \[51--104\]         69 \[48--98\]          0.03                                                1.00                                                0.48
  30-sec Balance test        11 \[1--16\]           6 \[0--13\]            8 \[1--18\]            7 \[1--11\]            0.04                                                0.67                                                1.00
  Power (Nm)                 103 \[60--150\]        120 \[80--60\]         121 \[60--180\]        114 \[60--180\]        0.01                                                1.00                                                0.32
  Flexion knee                                                                                                                                                                                                                   
  Right (Nm)                 63 \[39--97\]          80 \[38--149\]         80 \[35--128\]         75 \[40--100\]         0.99                                                1.00                                                1.00
  Left (Nm)                  62 \[42 - 95\]         78 \[33--137\]         84 \[43--157\]         76 \[35--101\]         1.00                                                0.56                                                1.00
  Extension knee                                                                                                                                                                                                                 
  Right (Nm)                 130 \[66--208\]        128 \[42--223\]        125 \[58--225\]        138 \[72--225\]        1.00                                                1.00                                                0.23
  Left (Nm)                  130 \[69 - 207\]       123 \[57--226\]        120 \[63--209\]        140 \[90--210\]        1.00                                                1.00                                                1.00
  Flexion elbow                                                                                                                                                                                                                  
  Right (Nm)                 49 \[28--67\]          47 \[27--84\]          52 \[27--86\]          52 \[33--82\]          1.00                                                0.89                                                1.00
  Left (Nm)                  46 \[24--72\]          46 \[27--76\]          47 \[30--69\]          52 \[31--76\]          1.00                                                1.00                                                1.00

Evolution in self-reported score regarding quality of life, functional and symptomatic scale \[EORTC -- C30\] ([Table 5](#t0005){ref-type="table"}) {#sec3.5}
---------------------------------------------------------------------------------------------------------------------------------------------------

Self-reported general functional performance showed statistically significant improvements. This improvement persisted up to the last assessment at the nine-month follow-up (p = 0.01, p = 0.02 and p = 0.04 at three, six and nine-month follow-up, respectively). Self-reported symptom scale improved at the three (13.5, range 0--35.9) and six-month follow-up (11.6, range 2.6--26.7), however, not significantly (p = 0.20 and p = 0.45 at three and six-month follow-up, respectively). There was a non-significant (p = 0.58) deterioration at the nine-month follow-up (16.7, range 5.1--38.5). The self-reported quality of life at three-month follow-up improved significantly (74.0 (range 25.0--100), p = 0.01) and maintained a steady state at the six (74.6, range 41.7--91.7) and nine-month (73.9, range 33.3--91.7) follow-up with no statistical significance (p = 1.00 at six and nine-month follow-up).

###### 

Evolution in quality of life regarding self-reported score

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          T0 Mean \[min--max\]   T3 Mean \[min--max\]   T6 Mean \[min--max\]   T9 Mean \[min--max\]   Group difference in mean change T0 ≥ T3 (p value)   Group difference in mean change T3 ≥ T6 (p value)   Group difference in mean change T6 ≥ T9 (p value)
  ----------------------- ---------------------- ---------------------- ---------------------- ---------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Functional scale        79.8\                  83.1\                  85.8\                  85.1\                  0.01                                                0.02                                                0.04
                          \[51.3--100\]          \[38.5--100\]          \[69.2--100\]          \[41.0--100\]                                                                                                                  

  Symptom scale           17.6\                  13.5\                  11.6\                  16.7\                  0.20                                                0,45                                                0.58
                          \[1.2 --35.9\]         \[0--35.9\]            \[2.6--26.7\]          \[5.1--38.5\]                                                                                                                  

  Quality of life scale   66.1\                  74.0\                  74.6\                  73.9\                  0.01                                                1.00                                                1.00
                          \[25.0--100\]          \[33.3--100\]          \[41.7--91.7\]         \[33.3--91.7\]                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DISCUSSION {#sec4}
==========

Prostate cancer is the second most common cancer in men worldwide and the most common in developed countries, where the mortality rate reaches 14.5 per 100,000 patients \[[@cit0001]\]. The highest incidence is recorded in Europe, North America and Oceania, largely because of the increased awareness and a wide availability and use of prostate-specific antigen \[[@cit0001], [@cit0011]\].

A significant remission of prostate cancer is seen after castration, which remains the cornerstone of treatment of advanced prostate cancer. Castration can be accomplished surgically (orchidectomy) or medically (androgen deprivation therapy) \[[@cit0012], [@cit0013]\]. Androgen deprivation therapy is used in approximately 45% of prostate cancer patients. It slows down tumor progression and improves the survival rate \[[@cit0014], [@cit0015]\].

Several adverse effects may occur in men with prostate cancer undergoing androgen deprivation therapy \[[@cit0016]\]. Those effects are mostly related to the unfavorable cardio-metabolic profile of androgen deprivation therapy and the concomitant hypo-androgenic status \[[@cit0017], [@cit0018]\]. On short term, it causes changes in the lipid and glucose-profile, leading to hyperinsulinemia, increased cholesterol, elevated total body fat and development of abdominal adiposity \[[@cit0019]\]. Furthermore, androgen deprivation therapy accelerates the bone and muscle loss and causes osteoporosis and fractures on the long-term \[[@cit0004], [@cit0020], [@cit0021]\]. Men on androgen deprivation therapy have a hypo-testosterone level resulting in sexual dysfunction, gynecomastia, hot flushes and fatigue \[[@cit0022], [@cit0023]\]. These side effects reduce the quality of life, including mood and cognition \[[@cit0024]\].

Prevention of androgen deprivation therapy-related side effects is a topic of increasing interest \[[@cit0014]\]. Physical exercise has been suggested to be the most beneficial, safe and cost-effective method to improve body composition in these patients \[[@cit0003], [@cit0016], [@cit0025], [@cit0026]\]. A combination of supervised resistance and aerobic training leads to an increase in lean mass and muscle strength \[[@cit0027]\]. A reduction of body fat was seen, as well as improvement in insulin sensitivity \[[@cit0005]\]. A systematic review by Gardner et al. shows that exercising improves physical performance and cardiorespiratory status, which -- on the long term -- contributes to preserving the patient\'s capacity for independent living \[[@cit0008]\].

Based on the pre-training assessment, we could state that the majority of the patients had an unfavorable cardio-metabolic profile, with hypercholesterolemia, hypertension, diabetes and obesity all present before the start of the training program. This unfavorable cardio-metabolic profile could lead to an underestimation of the cardio-vascular risk factors in patients with prostate cancer on androgen deprivation therapy. Considering that patients in a better general condition might be more motivated to participate in this program, the prevalence of cardio-vascular risk factors in this population could be even higher than our study shows. Since androgen deprivation therapy is associated with both cardiovascular disease and mortality \[[@cit0028]\], we emphasize the importance of screening and closer monitoring of cardio-vascular risk factors before and periodically after starting androgen deprivation therapy. Due to our small study-population, we were unable to demonstrate a statistically significant long term effect of exercise on the metabolic profile. However, several authors have shown a beneficial effect of physical training on multiple adverse effects of androgen deprivation therapy \[[@cit0006], [@cit0029], [@cit0030]\]. We expect to reach similar results by increasing the number of patients in this study in the future.

This pilot study shows that supervised physical exercise program positively improves physical performance in the short-term, particularly concerning muscular strength and balance. Galvão et al. and Beydoun et al. have shown similar findings in a larger series \[[@cit0031], [@cit0032]\]. Additionally, Gardner et al. describes comparable effects in their systematic review \[[@cit0008]\]. Despite the lack of a statistically significant effect of the training program on muscular strength, our data suggests a clinically meaningful effect of training, which could contribute to preserving a patient\'s capacity for independent living.

A positive effect of physical exercise related changes in self-reported quality of life was found in our study-population. Teleni et al. described comparable results, advocating that physical performance may contribute to an improved well-being \[[@cit0033]\]. These findings may motivate caretakers to give more attention to the overall impact of exercise on androgen deprivation therapy-related side effects in the future.

Our supervised physical exercise program was well tolerated by the study-population. No adverse events occurred during the study-period. Due to a close contact with our patients, we were able to collect useful feedback which revealed a very high satisfaction rate within the group.

We found that a supervised physical exercise program in small groups of six to eight patients might be more effective than an individual physical exercise program. We believe that social stimulation is extremely valuable, as it increases individual compliance and encourages maintaining a healthy lifestyle. These results are consistent with the findings of Galvão et al. \[[@cit0034]\]. Furthermore, Keogh et al. showed a better outcome for group-based supervised training in contrast to independent training and suggested that exercise counseling should be included in the daily care of patients with prostate cancer on androgen deprivation therapy \[[@cit0003]\].

The major limitations of our study lie within the small number of included patients and the lack of an age-matched control group with similar cardiovascular profiles, yet without androgen deprivation therapy, to compare with our study-population. Due to the low number of patients, several positive changes could not reach a statistically significant level. Furthermore, the control group could validate our results and thus the positive impact of physical exercise on the adverse influence of androgen deprivation therapy. However, the aim of this pilot-study was to check the feasibility of our study-design and a multicenter randomized controlled trial based on this study-design is therefore recommended in the future.

This pilot study used body mass index and abdominal circumference and was therefore only able to estimate a general body fat distribution (particularly truncal). To determine the exact change in body composition (fat versus lean mass), accurate measurements using a dual-energy X-ray absorptiometry or bio-impedance spectroscopy are needed \[[@cit0035]\]. However, those techniques are expensive and complex, and therefore not suitable for use on a daily basis.

Our pilot study assessed the health-related quality of life in patients with prostate cancer using only the EORTC-C30. To reach more qualitative results and clinical validity, a disease-specific module, such as the EORTC QLQ-PR25 (Prostate Cancer Module for QLQ-C30), should be added \[[@cit0036]\].

Finally, a future training program should include a general lifestyle intervention targeting a healthy individualized dietary behavior as an extra support \[[@cit0037]\].

CONCLUSIONS {#sec5}
===========

This pilot study revealed a remarkably unfavorable cardio-metabolic profile in patients with prostate cancer on androgen deprivation therapy. It is our belief that these risk factors are underdiagnosed in these patients. Therefore, we want to raise the awareness of clinicians for a metabolic risk assessment before starting androgen deprivation therapy and periodically thereafter. Furthermore, our study showed both statistically and clinically significant benefits of supervised physical exercise program in patients with prostate cancer on androgen deprivation therapy. This pilot study demonstrated that a supervised physical exercise program can reduce several androgen deprivation therapy-related side effects, improving general health status, self-reported as well as observed physical function and quality of life. We therefore recommend incorporating a supervised physical exercise program in the treatment of patients with prostate cancer on androgen deprivation therapy. A multi-center randomized controlled trial based on this pilot study design is therefore to confirm our findings.
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